Press Releases
Search
-
04 Apr 2018
bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical
bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions ...
-
28 Feb 2018
2017 Financial Results
Excellent sales momentum in 2017 with a 10.2% increase in sales, at constant exchange rates and scope of consolidation: €2,288 million in sales Up 8.8% as reported Strong 12.4% increase in contributiv...
-
23 Jan 2018
bioMérieux – Fourth-Quarter 2017 Business Review
Excellent sales momentum in 2017 with 10.2% growth in sales, at constant exchange rates and scope of consolidation: €2,288 million in sales Up 8.8% as reported Growth underpinned by all strategic prod...
-
15 Jan 2018
CNES and bioMérieux extend their collaboration on Aquapad, a unique water quality testing tool
Monday 15 January in Marcy l’Étoile (near Lyon), Proxima mission astronaut Thomas Pesquet detailed, during a conference, lessons learned from the Aquapad experiment he performed on the International S...
-
15 Dec 2017
Alexandre Mérieux appointed Chairman and CEO of bioMérieux
The Board of Directors of bioMérieux met today and approved the appointment of Alexandre Mérieux as Chairman and CEO of the Company, taking effect immediately. After serving as Deputy CEO of bioMérieu...
-
18 Oct 2017
bioMérieux – Business review for the nine months ended September 30, 2017
Solid growth in sales, up 10.7% at constant exchange rates and scope of consolidation €1,674 million in sales Up 10.8% as reported In microbiology, growth accelerated to nearly 8% Contribution from al...
-
30 Aug 2017
bioMérieux – First-Half 2017 Results
Solid sales dynamic, with sales up 11.3% over the first half at constant exchange rates and scope of consolidation: €1,134 million in sales Up 13.3% as reported 30-bp improvement in contributive opera...
-
31 Jul 2017
bioMérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VITEK® MS, its MALDI-TOF1 Mass Spectrometry System for rapid pathogen identification, has received 510(k) clearanc...
-
27 Jul 2017
Sysmex and bioMérieux Agreed to Dissolve the Joint Venture Sysmex bioMérieux Co., Ltd.
Sysmex Corporation (“Sysmex”) and bioMérieux S.A. (“bioMérieux”) (Paris:BIM) announce they have agreed to transfer all of Sysmex’ holdings in Sysmex bioMérieux Co., Ltd. (Tokyo, Japan) to bioMérieux t...
-
20 Jul 2017
Information financière du 2e trimestre 2017
Good sales dynamic confirmed in second-quarter 2017, with sales up 11.3% over the first half at constant exchange rates and scope of consolidation: €1,134 million in sales Up 13.3% as reported Noticea...
-
01 Jun 2017
boMérieux receives FDA Clearance for BioFire's FilmArray® Respiratory Panel 2 (RP2)
The FilmArray® RP2 reduces sample-to-result time to only 45 minutes while enhancing pathogen coverage and overall sensitivity...
-
20 Apr 2017
The FilmArray® Respiratory Panel 2 plus (RP2plus) gets CE marked
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that the FilmArray® Respiratory Panel 2 plus (RP2plus) is CE marked. The FilmArray® RP2plus panel tests for 22 pathogen...
-
20 Apr 2017
bioMérieux – First-Quarter 2017 Business Review
Strong sales dynamic in first-quarter 2017, with sales up 13.7% at constant exchange rates and scope of consolidation: €568 million in sales Up 16.3% as reported Equipment sales up sharply Accelerated...
-
05 Apr 2017
bioMérieux receives FDA 510(k) clearance for its BacT/ALERT® VIRTUO™ fully automated blood culture system
bioMérieux, a major player in the field of in vitro diagnostics, and the world leader in microbiology, announces that BacT/ALERT® VIRTUO™, its fully automated blood culture system, has received 510(k)...
-
01 Mar 2017
bioMérieux – 2016 Financial Results
Remarkable growth in sales in 2016, up 9.6% at constant exchange rates and scope of consolidation: €2,103 million in sales Up 7.1% as reported Contributive operating income before non-recurring items:...